Context: Tuberculosis (TB) is a common and often deadly infectious disease caused by strains of Mycobacteria. Development of new anti-tubercular drugs is essential to control the emergence and severity of multidrug-resistant TB.
Objective: The objective of this study was to develop an oral preclinical liquid formulation of SQ641 and to determine the permeability across rat intestinal tissue by Ussing chamber.
Methods: Thermal and chemical characterization of SQ641 was performed by differential scanning calorimetric analysis, thermogravimetric analysis and high performance liquid chromatography. A high throughput solubility screening technique was utilized to determine the solubility of SQ641 in different solvents and co-solvents. Several co-solvent and self-emulsifying drug delivery system (SEDDS) formulations were selected for Ussing chamber permeability studies.
Results And Discussion: Calculated average apparent permeability coefficients of SEDDS formulations of SQ641 (ranging from 0.03 × 10(-6) to 0.33 × 10(-6)) were found to be higher than the permeability coefficients of co-solvent formulations (ranging from 0.00 × 10(-6) to 0.09 × 10(-6)) and those of the neat drug SQ641 in buffer (0.00 × 10(-6)).
Conclusion: SEDDS formulations with superior permeability characteristics may provide a useful dosage form for oral intake of anti-tubercular drug SQ641, possibly due to the increase in solubility and immediate dispersion of drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10837450.2014.908304 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modular self-emulsifying drug delivery platform to enhance cellular uptake activity in triple-negative breast cancer.
Eur J Pharm Sci
December 2024
Massachusetts College of Pharmacy and Health Sciences (MCPHS University) Department of Pharmaceutical Sciences, School of Pharmacy, 19 Foster St., Worcester, MA 01608, USA. Electronic address:
Triple-negative breast cancer (TNBC) presents with resistance phenotypes to certain therapies, such as cisplatin, often requiring higher dosing, with associated acquired tumor resistance, renal toxicity, and variable patient responses. A self-emulsifying drug delivery (SEDD) formulation approach was proposed to overcome the limitations of cisplatin in TNBC, focusing on improving intracellular cisplatin and control siRNA uptake as a proof-of-principle of dual drug delivery. Four SEDD formulations were prepared and optimized for cisplatin (o/w) emulsion and FITC-siRNA (w/o) emulsion using pseudo-ternary phase diagrams to facilitate the formation of water-in-oil-water (w/o/w) emulsions.
View Article and Find Full Text PDFImpact of non-ionic surfactants on release kinetics, toxicity and colloidal characteristics of benznidazole self-emulsifying delivery system evidenced by flow field-flow fractionation.
J Chromatogr A
November 2024
Laboratory of Pharmaceutics and Nanotechnology (LDGNano), School of Pharmacy, Federal University of Ouro Preto, Minas Gerais 35400-000, Brazil. Electronic address:
Chagas disease is the major cause of death by cardiomyopathy in Latin America. Benznidazole (BZN) tablets are the standard of care for Chagas disease, and recently, self-emulsifying systems (SEDDS) have shown promising efficacy as the BZN delivery system, particularly for pediatric use. However, the comparative effects of surfactants on the physicochemical properties of SEDDS have been poorly investigated to date.
View Article and Find Full Text PDFDevelopment, Analysis, and Determination of Pharmacokinetic Properties of a Solid SMEDDS of Voriconazole for Enhanced Antifungal Therapy.
Life (Basel)
November 2024
Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Background: Voriconazole is an antifungal drug, which is classified under Bio-Classification System-II and has low water solubility (0.71 mg/mL) and high permeability. Hardly any endeavors have been made to increase the bioavailability of voriconazole.
View Article and Find Full Text PDFDesign of self-emulsifying oral delivery systems for semaglutide: reverse micelles versus hydrophobic ion pairs.
Drug Deliv Transl Res
October 2024
Department of Pharmaceutical Technology, Institute of Pharmacy, Center for Chemistry and Biomedicine, University of Innsbruck, Innsbruck, 6020, Austria.
It was the aim of this study to evaluate the potential of reverse micelles (RM) and hydrophobic ion pairs (HIP) for incorporation of semaglutide into self-emulsifying oral drug delivery systems. Reverse micelles loaded with semaglutide were formed with a cationic (ethyl lauroyl arginate, ELA) and an anionic surfactant (docusate, DOC), whereas HIP were formed between semaglutide and ELA. Maximum solubility of the peptide and the rate of dissolution was evaluated in various lipophilic phases (glycerol monocaprylocaprate:caprylic acid 1:4 (m/m), glycerol monolinoleate:caprylic acid 1:4 (m/m) and glycerol monocaprylocaprate:glycerol monolinoleate 1:4 (m/m)).
View Article and Find Full Text PDFSingle-Step Extrusion Process for Formulation Development of Self-Emulsifying Granules for Oral Delivery of a BCS Class IV Drug.
Mol Pharm
December 2024
Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, Mississippi 38677, United States.
Article Synopsis
- This study focuses on improving the solubility and permeability of a BCS Class IV drug by developing self-emulsifying solid lipid matrices as a new form of drug delivery system.
- Self-emulsifying drug delivery systems (SEDDS) are helpful for poorly soluble drugs but face manufacturing challenges like low drug loading and stability issues.
- The research explores using a single-step extrusion process to create solid self-emulsifying granules with higher drug loading, which demonstrated significantly improved solubility and permeability, enhancing the potential for effective drug delivery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!